All In Biotech

Drug Trial Radar · NCT05702983

The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects

An Open-label, Single-ascending Dose, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STSA-1002 Subcutaneous Injection in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: May 26, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Jan 31, 2023

Primary completion

Apr 11, 2023

Study completion Apr 24, 2023

Sponsor

Sponsor type
Industry
First posted
Jan 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 57 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

An Open-label, Single-ascending dose, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STSA-1002 Subcutaneous Injection in Healthy Subjects

Conditions

  • Antineutrophil Cytoplasmic Antibody Associated Vasculitis

Interventions

  • STSA-1002 subcutaneous injectionDrug

    Subjects will receive a single low dose on day 1 following protocol requirements.

  • STSA-1002 subcutaneous injectionDrug

    Subjects will receive a single high dose on day 1 following protocol requirements.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of treatment-related adverse events as assessed by toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trialsTime frame: 50 days
  2. Abnormal clinical laboratory values as assessed by toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials (blood hematology, blood chemistry, urinalysis, etc.)Time frame: 50 days
  3. Abnormal vital signs as assessed by toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials (body temperature, pulse rate, blood pressure and respiratory rate)Time frame: 50 days
  4. Abnormal physical examinationTime frame: 50 days
  5. Abnormal electrocardiogram (ECG): heart rate, PR and QT intervals, QTcF and QRS durationTime frame: 50 days
  6. Maximum plasma concentration (Cmax)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
  7. area under the plasma concentration-time curve from time 0 to the collection time point t of the last measurable concentration (AUC0-t)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
  8. area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
  9. Time of maximum concentration (Tmax)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
  10. elimination half-life (t1/2)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
  11. elimination rate constant of plasma drug concentration in terminal phase (λz)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
  12. last measurable concentration (Clast)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
  13. mean residence time (MRT)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
  14. clearance (CL)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours
  15. apparent volume of distribution (Vz)Time frame: Pre-dose; after dose 8hours, 24hours, 48hours, 72hours, 96hours, 120hours, 168hours, 336hours, 504hours, 840hours, 1176hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • AltaSciences Clinical Kansas, Inc

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.